$INFU
InfuSystem Holdings, Inc Stock $infu

$infu Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000143774921011559 Filed on May 10, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$24.46M	$21.55M
YoY Change	13.5%	18.47%
Cost Of Revenue	$9.887M	$8.890M
YoY Change	11.21%	13.22%
Gross Profit	$14.58M	$12.66M
YoY Change	15.11%	22.45%
Gross Profit Margin	59.58%	58.75%
Selling, General & Admin	$12.73M	$11.27M
YoY Change	12.95%	15.78%
% of Gross Profit	87.34%	89.0%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.527M	$2.328M
YoY Change	8.55%	90.04%
% of Gross Profit	17.34%	18.38%
Operating Expenses	$13.70M	$12.63M
YoY Change	8.5%	17.37%
Operating Profit	$873.0K	$33.00K
YoY Change	2545.45%	-107.86%
Interest Expense	$322.0K	$403.0K
YoY Change	-20.1%	-12.39%
% of Operating Profit	36.88%	1221.21%
Other Income/Expense, Net	-$69.00K	-$19.00K
YoY Change	263.16%	-9.52%
Pretax Income	$482.0K	-$389.0K
YoY Change	-223.91%	-56.83%
Income Tax	-$179.0K	$29.00K
% Of Pretax Income	-37.14%
Net Earnings	$661.0K	-$418.0K
YoY Change	-258.13%	-56.46%
Net Earnings / Revenue	2.7%	-1.94%
Basic Earnings Per Share	$0.03	-$0.02
Diluted Earnings Per Share	$0.03	-$0.02
COMMON SHARES
Basic Shares Outstanding	20.34M shares	19.92M
Diluted Shares Outstanding	21.94M shares	19.92M

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.761M	$305.0K
YoY Change	805.25%	-83.95%
Cash & Equivalents	$2.761M	$305.0K
Short-Term Investments
Other Short-Term Assets	$2.804M	$2.002M
YoY Change	40.06%	36.19%
Inventory	$3.229M	$4.232M
Prepaid Expenses
Receivables	$14.69M	$13.99M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$23.49M	$20.52M
YoY Change	14.44%	25.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.327M	$4.382M
YoY Change	-1.26%	220.32%
Goodwill
YoY Change
Intangibles	$11.32M	$14.39M
YoY Change	-21.32%	-23.22%
Long-Term Investments
YoY Change
Other Assets	$115.0K	$158.0K
YoY Change	-27.22%	6.04%
Total Long-Term Assets	$67.10M	$62.15M
YoY Change	7.96%	22.24%
TOTAL ASSETS
Total Short-Term Assets	$23.49M	$20.52M
Total Long-Term Assets	$67.10M	$62.15M
Total Assets	$90.59M	$82.68M
YoY Change	9.57%	22.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.553M	$12.80M
YoY Change	-48.78%	32.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$671.0K	$7.295M
YoY Change	-90.8%	36.69%
Total Short-Term Liabilities	$12.16M	$23.80M
YoY Change	-48.91%	28.81%
LONG-TERM LIABILITIES
Long-Term Debt	$31.75M	$32.33M
YoY Change	-1.79%	17.46%
Other Long-Term Liabilities	$3.733M	$4.422M
YoY Change	-15.58%	198.99%
Total Long-Term Liabilities	$31.75M	$32.33M
YoY Change	-1.79%	-31.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.16M	$23.80M
Total Long-Term Liabilities	$31.75M	$32.33M
Total Liabilities	$47.64M	$60.66M
YoY Change	-21.46%	-8.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$43.37M	-$61.79M
YoY Change	-29.8%	-2.99%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$42.95M	$22.02M
YoY Change
Total Liabilities & Shareholders Equity	$90.59M	$82.68M
YoY Change	9.57%	22.95%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	$661.0K	-$418.0K
YoY Change	-258.13%	-56.46%
Depreciation, Depletion And Amortization	$2.527M	$2.328M
YoY Change	8.55%	90.04%
Cash From Operating Activities	$2.651M	$557.0K
YoY Change	375.94%	-56.11%
INVESTING ACTIVITIES
Capital Expenditures	$138.0K	$529.0K
YoY Change	-73.91%	-114.96%
Acquisitions	$1.204M
YoY Change
Other Investing Activities	-$328.0K	$500.0K
YoY Change	-165.6%	-34.55%
Cash From Investing Activities	-$2.802M	-$4.036M
YoY Change	-30.57%	45.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$250.0K
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$6.736M	$1.137M
YoY Change	-692.44%	-224.13%
NET CHANGE
Cash From Operating Activities	$2.651M	$557.0K
Cash From Investing Activities	-$2.802M	-$4.036M
Cash From Financing Activities	-$6.736M	$1.137M
Net Change In Cash	-$6.887M	-$2.342M
YoY Change	194.06%	-3.14%
FREE CASH FLOW
Cash From Operating Activities	$2.651M	$557.0K
Capital Expenditures	$138.0K	$529.0K
Free Cash Flow	$2.513M	$28.00K
YoY Change	8875.0%	-99.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	InfuSystem Holdings, Inc
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001337013
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20468797
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23915091
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20396602
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23816193
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20297704
CY2020Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	200000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2761000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9648000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14693000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14720000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	3229000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3001000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2804000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2402000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	23487000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	29771000	USD
CY2021Q1	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	1045000	USD
CY2020Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	1603000	USD
CY2021Q1	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	35769000	USD
CY2020Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	35611000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4327000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4296000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11321000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11177000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4376000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4461000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	10147000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9967000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	115000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	105000	USD
CY2021Q1	us-gaap	Assets Assets	90587000	USD
CY2020Q4	us-gaap	Assets Assets	96991000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6553000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6779000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	671000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9423000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4934000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6795000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12158000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22997000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	42949000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	40752000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90587000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96991000	USD
CY2021Q1	us-gaap	Revenues Revenues	24463000	USD
CY2020Q1	us-gaap	Revenues Revenues	21553000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9887000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8890000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	14576000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	12663000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-70000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	285000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1043000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1075000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	31747000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29378000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3733000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2376000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2618000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10354000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8652000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3864000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	47638000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	56239000	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	13703000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-418000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	158000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86163000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84785000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	158000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43374000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44035000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	12630000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	873000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	33000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	322000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	403000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-69000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	482000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-389000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-179000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	661000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-418000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20338160
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19918298
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21937639
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19918298
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	661000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	819000	USD
CY2021Q1	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	2336000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-418000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	22334000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	206000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	74000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	426000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	250000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-418000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	22020000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	40752000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	139000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1635000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	169000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	565000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	158000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	661000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	42949000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	661000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-418000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-70000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	285000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	2527000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	2328000	USD
CY2021Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	597000	USD
CY2020Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	105000	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-89000	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1140000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1043000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1075000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	96000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1635000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	206000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-180000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	420000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1628000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	154000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1333000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	244000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	340000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	40000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	19000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2889000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1423000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2651000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	557000	USD
CY2021Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1204000	USD
CY2020Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	-0	USD
CY2020Q1	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	4007000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	529000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	876000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	500000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2802000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4036000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	40093000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	9229000	USD
CY2021Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	34000000	USD
CY2020Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	10468000	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	386000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	565000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	426000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	308000	USD
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	74000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	250000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6736000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1137000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6887000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2342000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9648000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2647000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2761000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	305000	USD
CY2021Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><b>Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are <em style="font: inherit;">not</em> necessarily indicative of results that <em style="font: inherit;"> may </em>be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2020 </em>as filed with the SEC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i/></p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Derivatives Accounting Policy</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to Accumulated Other Comprehensive Income in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued, the applicable amount of gain or loss included in Accumulated Other Comprehensive Income is reclassified in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settle on a net basis.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The fair value of the Company’s derivative financial instruments are categorized as Level <em style="font: inherit;">2</em> of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"/>
CY2021Q1	us-gaap	Revenues Revenues	24463000	USD
CY2020Q1	us-gaap	Revenues Revenues	21553000	USD
CY2021Q1	infu	Medical Equipment Held For Sale Or Rental Gross MedicalEquipmentHeldForSaleOrRentalGross	1107000	USD
CY2020Q4	infu	Medical Equipment Held For Sale Or Rental Gross MedicalEquipmentHeldForSaleOrRentalGross	1636000	USD
CY2021Q1	infu	Medical Equipment For Sale Or Rental Reserve MedicalEquipmentForSaleOrRentalReserve	62000	USD
CY2020Q4	infu	Medical Equipment For Sale Or Rental Reserve MedicalEquipmentForSaleOrRentalReserve	33000	USD
CY2021Q1	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	1045000	USD
CY2020Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	1603000	USD
CY2021Q1	infu	Medical Equipment In Rental Services Gross MedicalEquipmentInRentalServicesGross	85080000	USD
CY2020Q4	infu	Medical Equipment In Rental Services Gross MedicalEquipmentInRentalServicesGross	83411000	USD
CY2021Q1	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	1332000	USD
CY2020Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	893000	USD
CY2021Q1	infu	Medical Equipment In Rental Services Accumulated Depreciation MedicalEquipmentInRentalServicesAccumulatedDepreciation	47979000	USD
CY2020Q4	infu	Medical Equipment In Rental Services Accumulated Depreciation MedicalEquipmentInRentalServicesAccumulatedDepreciation	46907000	USD
CY2021Q1	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	35769000	USD
CY2020Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	35611000	USD
CY2021Q1	infu	Medical Equipment Net MedicalEquipmentNet	36814000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3196000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11321000	USD
CY2020Q4	infu	Medical Equipment Net MedicalEquipmentNet	37214000	USD
CY2021Q1	infu	Depreciation Expense Related To Medical Equipment DepreciationExpenseRelatedToMedicalEquipment	2300000	USD
CY2020Q1	infu	Depreciation Expense Related To Medical Equipment DepreciationExpenseRelatedToMedicalEquipment	2100000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7523000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4327000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7275000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2979000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4296000	USD
CY2021Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	200000	USD
CY2021Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	50973000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	39652000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	49787000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	38610000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11177000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2021Q1	infu	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	281000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	551000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	222000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2021Q1	infu	Longterm Debt Maturities Repayments Of Principal Year Four And Thereafter LongtermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter	32000000	USD
CY2021Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32773000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3043000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2221000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	717000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	717000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	537000	USD
CY2021Q1	infu	Finitelived Intangible Asset Expected Amortization Year Five And After FinitelivedIntangibleAssetExpectedAmortizationYearFiveAndAfter	2086000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9321000	USD
CY2021Q1	infu	Longterm Debt Gross Current LongtermDebtGrossCurrent	745000	USD
CY2021Q1	infu	Longterm Debt Gross Noncurrent LongtermDebtGrossNoncurrent	32028000	USD
CY2021Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32773000	USD
CY2020Q4	infu	Longterm Debt Gross Current LongtermDebtGrossCurrent	9440000	USD
CY2020Q4	infu	Longterm Debt Gross Noncurrent LongtermDebtGrossNoncurrent	29427000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	38867000	USD
CY2021Q1	infu	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	74000	USD
CY2021Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	355000	USD
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1599479
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
CY2020Q4	infu	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	17000	USD
CY2020Q4	infu	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	49000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	66000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	671000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	31747000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	32418000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9423000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29378000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	38801000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	661000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-418000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20338160
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19918298
CY2021Q1	infu	Revenues External RevenuesExternal	24463000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	405000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	536000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	375000	USD
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21937639
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19918298
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	348000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	424000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	57000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	112000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	451000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	281000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	118000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077	pure
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077	pure
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	830000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1179000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	979000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	949000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	914000	USD
CY2021Q1	infu	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	2253000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7104000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2347000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4757000	USD
CY2021Q1	infu	Revenues Internal RevenuesInternal	0	USD
CY2021Q1	us-gaap	Revenues Revenues	24463000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	14576000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	13703000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	322000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-69000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-179000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	661000	USD
CY2021Q1	us-gaap	Assets Assets	90587000	USD
CY2021Q1	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	2336000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3570000	USD
CY2020Q1	infu	Revenues External RevenuesExternal	21553000	USD
CY2020Q1	infu	Revenues Internal RevenuesInternal	0	USD
CY2020Q1	us-gaap	Revenues Revenues	21553000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	12663000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	12630000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	403000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-418000	USD
CY2020Q1	us-gaap	Assets Assets	82678000	USD
CY2020Q1	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	4007000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3402000	USD

Files In Submission

Name	View Source	Status
0001437749-21-011559-index-headers.html	Edgar Link	pending
0001437749-21-011559-index.html	Edgar Link	pending
0001437749-21-011559.txt	Edgar Link	pending
0001437749-21-011559-xbrl.zip	Edgar Link	pending
ex_245824.htm	Edgar Link	pending
ex_245825.htm	Edgar Link	pending
ex_245826.htm	Edgar Link	pending
ex_245827.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
infu-20210331.xsd	Edgar Link	pending
infu-20210331_cal.xml	Edgar Link	unprocessable
infu-20210331_def.xml	Edgar Link	unprocessable
infu-20210331_lab.xml	Edgar Link	unprocessable
infu-20210331_pre.xml	Edgar Link	unprocessable
infu20210331_10q.htm	Edgar Link	pending
infu20210331_10q_htm.xml	Edgar Link	completed
logo.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INFU
InfuSystem Holdings, Inc Stock $infu

2021 Q1 Form 10-Q Financial Statement

#000143774921011559 Filed on May 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INFU InfuSystem Holdings, Inc Stock $infu

2021 Q1 Form 10-Q Financial Statement

#000143774921011559 Filed on May 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INFU
InfuSystem Holdings, Inc Stock $infu